Clinical Trial Update: Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses [Phase 2, Phase 3]

View source ↗

Summary

This ClinicalTrials.gov entry indicates that a Phase 2/Phase 3 trial of celecoxib to prevent skin cancer in patients with actinic keratoses has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis
• Skin Cancer

Drugs mentioned

• Celecoxib (Celecoxib)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Precancerous Condition | Phase 2, Phase 3 | Status: WITHDRAWN